Defensive Neurosurgery Up in States With High Liability Risk

Share this content:
Defensive Neurosurgery Up in States With High Liability Risk
Defensive Neurosurgery Up in States With High Liability Risk

THURSDAY, Feb. 12, 2015 (HealthDay News) -- Neurosurgeons are more likely to practice defensive medicine in states with high state-level liability risk, according to a study published in the February issue of Neurosurgery.

Timothy R. Smith, M.D., Ph.D., M.P.H., from Northwestern University in Chicago, and colleagues examined the correlation of defensive medicine with the liability environment. Data were collected from 1,026 neurosurgeons' responses to a 51-question online survey. The survey, which had previously been validated, included questions related to neurosurgeon, practice, and patient characteristics; perceptions of the liability environment; and defensive medicine behaviors.

The researchers found that 83 percent of respondents correctly identified that they were practicing in a high-risk environment, indicating that neurosurgeons' perceptions of their state's liability environment generally corresponded to objective measures of state-level liability risk. Neurosurgeons were 50 percent more likely to practice defensive medicine in high-risk states versus low-risk states, after adjustment for surgeon experience, income, high-risk patient load, liability history, and type of patient insurance.

"Both avoidance and assurance behaviors are prevalent among U.S. neurosurgeons and are correlated with subjective and objective measures of state-level liability risk," the authors write. "Defensive medicine practices do not align with patient-centered care and may contribute to increased inefficiency in an already taxed health care system."

Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »